Abstract | BACKGROUND: METHODS: A retrospective review of all clubfoot patients at British Columbia's Children Hospital, less than 2 years of age, who received a Onabotulinumtoxin A injection for equinus correction, between September 2000 and December 2012 was conducted. Data collected included demographics, clinical diagnosis, treatment history, ankle range of motion and any adverse event noted by the clubfoot team or reported by the families. RESULTS: CONCLUSIONS:
Onabotulinumtoxin A appears to be safe with respect to the adverse events, for use in children under 2 years of age with the diagnosis of clubfoot when dosed at 10 units per kilogram. However, the dose of Onabotulinumtoxin A and underlying diagnosis should always be kept in mind.
|
Authors | Harpreet Chhina, Alyssa Howren, Andrea Simmonds, Christine M Alvarez |
Journal | European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
(Eur J Paediatr Neurol)
Vol. 18
Issue 2
Pg. 171-5
(Mar 2014)
ISSN: 1532-2130 [Electronic] England |
PMID | 24268889
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Botulinum Toxins, Type A
(adverse effects)
- Child, Preschool
- Clubfoot
(drug therapy)
- Female
- Hospitals, Pediatric
(statistics & numerical data)
- Humans
- Infant
- Infant, Newborn
- Neuromuscular Agents
(adverse effects)
- Retrospective Studies
- Treatment Outcome
|